Optomed (OPTOMED.HE) Stock Analysis & AI Equity Report
Optomed (OPTOMED.HE) overview
Optomed (OPTOMED.HE) stock analysis and AI equity research. For the latest completed financial year, 2025, Optomed reported revenue of EUR 17.1m and operating profit of EUR -6.0m; the year-end share price was 3.77 EUR and market capitalisation was EUR 74.7m. Optomed is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Optomed's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-23. Data will be refreshed during report generation.
About Optomed
Optomed is a Finnish medical technology company that develops handheld and tabletop fundus cameras, retinal imaging devices, and ophthalmology software. Its products support eye screening, image capture, and workflow management for detecting and monitoring diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration across primary care, clinics, and screening programs.
Generate the Optomed report
Optomed is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Optomed and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.